These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

978 related articles for article (PubMed ID: 23453151)

  • 1. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
    Daróczi B; Szántó E; Tóth J; Barzó P; Bognár L; Bakó G; Szántó J; Mózes P; Hideghéty K
    Ideggyogy Sz; 2013 Nov; 66(11-12):391-8. PubMed ID: 24555238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
    Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
    J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide : A mono-institutional experience of 215 patients.
    Julka PK; Sharma DN; Mallick S; Gandhi AK; Joshi N; Rath GK
    J Cancer Res Ther; 2013; 9(3):381-6. PubMed ID: 24125970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
    Marina O; Suh JH; Reddy CA; Barnett GH; Vogelbaum MA; Peereboom DM; Stevens GH; Elinzano H; Chao ST
    J Neurosurg; 2011 Aug; 115(2):220-9. PubMed ID: 21548745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.